Researchers Build Prognostic Model for Leukemia
A new laboratory-based model predicts disease progression for chronic lymphocytic leukemia patients receiving targeted therapies.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you believe personalized diagnostic testing should play a larger role in your medical treatment plan?
Researchers have developed a functional prognostic model for chronic lymphocytic leukemia that uses baseline patient samples to forecast progression-free survival. Published in 2026, the study demonstrates that this tool can outperform standard clinical scoring systems.
Why it matters
Novel prognostic markers are essential for tailoring treatment plans, as patient responses to targeted therapies like ibrutinib and venetoclax remain highly heterogeneous. This approach seeks to provide more precise risk stratification than existing clinical methods.
The study analyzed baseline peripheral blood mononuclear cells from 177 patients to build the model. It achieved a 0.805 time-averaged ROC-AUC in a blinded validation set.
The players
HemaSphere
This is a peer-reviewed medical journal that publishes research related to hematology and blood disorders.
The details
The model utilizes six laboratory features, including ex vivo drug sensitivity and the proportion of CD8-positive T cells, to assess risk. Researchers found that higher CD8-positive T-cell levels correlate with increased progression risk, while higher drug sensitivity indicates more favorable outcomes.
Timeline
The prognostic model study was published in HemaSphere in 2026.
Health Landscape
This research signals a shift toward functional biological profiling in cancer care, moving beyond legacy genetic markers like IGHV status. It marks a departure from reliance on the CLL-IPI clinical scoring system by prioritizing functional laboratory markers over traditional genetic data.
This development suggests that future clinical management could rely on laboratory-based tests of a patient's own cells rather than genetic markers alone. Such advancements may one day help clinicians better predict if specific drug combinations like ibrutinib and venetoclax will be effective for individual patients.
The takeaway
This model highlights the potential for personalized medicine by using functional lab data to navigate treatment complexity. Prospective clinical trials will be the necessary next step to verify if these findings can be safely translated into standard medical practice.
Further reading
Learn more about the latest research in blood-related malignancies on our Cancer page.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you believe personalized diagnostic testing should play a larger role in your medical treatment plan?
